Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499 /month or less, regardless of insurance ...

who now have another treatment option for this sleep disorder,” according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the AASM noted.